JP6186361B2 - 代謝障害を処置するための融合タンパク質 - Google Patents

代謝障害を処置するための融合タンパク質 Download PDF

Info

Publication number
JP6186361B2
JP6186361B2 JP2014532117A JP2014532117A JP6186361B2 JP 6186361 B2 JP6186361 B2 JP 6186361B2 JP 2014532117 A JP2014532117 A JP 2014532117A JP 2014532117 A JP2014532117 A JP 2014532117A JP 6186361 B2 JP6186361 B2 JP 6186361B2
Authority
JP
Japan
Prior art keywords
fgf21
fusion protein
protein
amino acid
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014532117A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014534172A (ja
Inventor
ブライアン・アール・ボーチャー
シャリ・エル・キャプラン
ダグラス・エス・ダニエルズ
典郎 浜松
典郎 浜松
スチュアート・リクト
スティーブン・クレイグ・ウェルドン
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2014534172A publication Critical patent/JP2014534172A/ja
Application granted granted Critical
Publication of JP6186361B2 publication Critical patent/JP6186361B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2014532117A 2011-09-26 2012-09-26 代謝障害を処置するための融合タンパク質 Active JP6186361B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161539280P 2011-09-26 2011-09-26
US61/539,280 2011-09-26
PCT/US2012/057384 WO2013049247A1 (en) 2011-09-26 2012-09-26 Fusion proteins for treating metabolic disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017146984A Division JP6567613B2 (ja) 2011-09-26 2017-07-28 代謝障害を処置するための融合タンパク質

Publications (2)

Publication Number Publication Date
JP2014534172A JP2014534172A (ja) 2014-12-18
JP6186361B2 true JP6186361B2 (ja) 2017-08-23

Family

ID=46970456

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2014532117A Active JP6186361B2 (ja) 2011-09-26 2012-09-26 代謝障害を処置するための融合タンパク質
JP2017146984A Active JP6567613B2 (ja) 2011-09-26 2017-07-28 代謝障害を処置するための融合タンパク質
JP2019141242A Withdrawn JP2020007314A (ja) 2011-09-26 2019-07-31 代謝障害を処置するための融合タンパク質
JP2022002030A Active JP7339372B2 (ja) 2011-09-26 2022-01-11 代謝障害を処置するための融合タンパク質

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017146984A Active JP6567613B2 (ja) 2011-09-26 2017-07-28 代謝障害を処置するための融合タンパク質
JP2019141242A Withdrawn JP2020007314A (ja) 2011-09-26 2019-07-31 代謝障害を処置するための融合タンパク質
JP2022002030A Active JP7339372B2 (ja) 2011-09-26 2022-01-11 代謝障害を処置するための融合タンパク質

Country Status (41)

Country Link
US (6) US9006400B2 (cg-RX-API-DMAC7.html)
EP (2) EP2760475B1 (cg-RX-API-DMAC7.html)
JP (4) JP6186361B2 (cg-RX-API-DMAC7.html)
KR (1) KR102085605B1 (cg-RX-API-DMAC7.html)
CN (2) CN103945871B (cg-RX-API-DMAC7.html)
AP (1) AP2014007543A0 (cg-RX-API-DMAC7.html)
AR (2) AR088044A1 (cg-RX-API-DMAC7.html)
AU (1) AU2012316052A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014007069B1 (cg-RX-API-DMAC7.html)
CA (1) CA2849464C (cg-RX-API-DMAC7.html)
CL (2) CL2014000736A1 (cg-RX-API-DMAC7.html)
CO (1) CO6920257A2 (cg-RX-API-DMAC7.html)
CR (1) CR20140140A (cg-RX-API-DMAC7.html)
CU (2) CU24314B1 (cg-RX-API-DMAC7.html)
CY (2) CY1120928T1 (cg-RX-API-DMAC7.html)
DK (2) DK3321276T3 (cg-RX-API-DMAC7.html)
EA (1) EA039633B1 (cg-RX-API-DMAC7.html)
ES (2) ES2895080T3 (cg-RX-API-DMAC7.html)
GT (1) GT201400055A (cg-RX-API-DMAC7.html)
HR (2) HRP20211575T1 (cg-RX-API-DMAC7.html)
HU (2) HUE039857T2 (cg-RX-API-DMAC7.html)
IL (1) IL231533B (cg-RX-API-DMAC7.html)
IN (1) IN2014DN02043A (cg-RX-API-DMAC7.html)
JO (1) JO3476B1 (cg-RX-API-DMAC7.html)
LT (2) LT3321276T (cg-RX-API-DMAC7.html)
MA (1) MA35437B1 (cg-RX-API-DMAC7.html)
MX (1) MX350273B (cg-RX-API-DMAC7.html)
MY (1) MY166059A (cg-RX-API-DMAC7.html)
PE (2) PE20181159A1 (cg-RX-API-DMAC7.html)
PL (2) PL2760475T3 (cg-RX-API-DMAC7.html)
PT (2) PT2760475T (cg-RX-API-DMAC7.html)
RS (2) RS57868B1 (cg-RX-API-DMAC7.html)
SG (2) SG11201400538QA (cg-RX-API-DMAC7.html)
SI (2) SI2760475T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100595T1 (cg-RX-API-DMAC7.html)
TN (1) TN2014000109A1 (cg-RX-API-DMAC7.html)
TW (1) TWI593708B (cg-RX-API-DMAC7.html)
UA (1) UA113856C2 (cg-RX-API-DMAC7.html)
UY (2) UY34346A (cg-RX-API-DMAC7.html)
WO (1) WO2013049247A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201401700B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020007314A (ja) * 2011-09-26 2020-01-16 ノバルティス アーゲー 代謝障害を処置するための融合タンパク質

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008012525A1 (en) 2006-07-25 2008-01-31 Lipoxen Technologies Limited Derivatisation of granulocyte colony-stimulating factor
CN107501407B (zh) 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES3005233T3 (en) 2010-10-01 2025-03-14 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US8951966B2 (en) 2011-07-01 2015-02-10 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
TW201315742A (zh) 2011-09-26 2013-04-16 Novartis Ag 治療代謝病症之雙功能蛋白質
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
AU2012352180A1 (en) 2011-12-16 2014-07-31 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
WO2014085365A2 (en) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
DK2938740T3 (da) 2012-12-27 2022-06-20 Ngm Biopharmaceuticals Inc Kimære fgf19-peptider til anvendelse til behandling af galdesyrelidelser
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
WO2015057908A1 (en) 2013-10-18 2015-04-23 Novartis Ag Methods of treating diabetes and related disorders
WO2015065897A1 (en) 2013-10-28 2015-05-07 Ngm Biopharmaceuticals, Inc. Cancer models and associated methods
CN106662577B (zh) 2014-01-24 2020-07-21 恩格姆生物制药公司 结合蛋白及其使用方法
JP6712230B2 (ja) * 2014-03-11 2020-06-17 ノバルティス アーゲー リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2016065106A1 (en) * 2014-10-23 2016-04-28 Ngm Biopharmaceuticals, Inc. Pharmaceutical compositions comprising peptide variants and methods of use thereof
UY36370A (es) 2014-10-24 2016-04-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Polipéptidos fgf-21 modificados y sus usos
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
KR20160088656A (ko) 2015-01-16 2016-07-26 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
EP3331914A1 (en) 2015-08-03 2018-06-13 Novartis AG Methods of treating fgf21-associated disorders
KR102670157B1 (ko) * 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
WO2017083276A1 (en) 2015-11-09 2017-05-18 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
TW201731867A (zh) * 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體
US12281154B2 (en) * 2016-05-20 2025-04-22 President And Fellows Of Harvard College Gene therapy methods for age-related diseases and conditions
US11318186B2 (en) 2016-05-25 2022-05-03 Board Of Regents, The University Of Texas System Use of FGF21 in methods of increasing exocrine pancreatic secretion
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN107759696A (zh) * 2016-08-19 2018-03-06 安源医药科技（上海）有限公司 人白介素7融合蛋白及其制备方法
US11123438B2 (en) 2016-08-19 2021-09-21 Ampsource Biopharma Shanghai Inc. Linker peptide for constructing fusion protein
CA3034399A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
CN110087671A (zh) 2016-12-22 2019-08-02 赛诺菲 具有优化的活性比率的fgf21化合物/glp-1r激动剂组合
WO2018166461A1 (en) * 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
CN107050429B (zh) * 2017-04-01 2020-12-15 杭州生物医药创新研究中心 人成纤维生长因子21在制备用于治疗脑卒中药物中的应用
ES3041527T3 (en) * 2017-05-05 2025-11-12 Trefoil Therapeutics Inc Recombinant modified fibroblast growth factors and therapeutic uses thereof
CN115109166B (zh) * 2017-11-24 2025-07-18 浙江道尔生物科技有限公司 一种治疗代谢疾病的多结构域活性蛋白
US11752173B2 (en) 2017-12-19 2023-09-12 Beijing Jiyuan Biological Technology Co., Ltd. FGF21 and GLP1 double gene-modified mesenchymal stem cell and use in treating a metabolic disease
RS65720B1 (sr) * 2017-12-22 2024-08-30 Novartis Ag Tretiranje metaboličkih poremećaja pomoću fgf21 varijanti
EP3749683A4 (en) 2018-02-08 2022-03-16 Sunshine Lake Pharma Co., Ltd. FGF21 VARIANT, FUSION PROTEIN AND USE THEREOF
JP2021528422A (ja) * 2018-06-21 2021-10-21 サノフイＳａｎｏｆｉ 最適化された活性比を有するｆｇｆ２１化合物／ｇｌｐ−１ｒアゴニストの組合せ
BR112020026512A2 (pt) 2018-07-03 2021-04-06 Bristol-Myers Squibb Company Formulações de fgf-21
CN111195234B (zh) * 2018-11-16 2022-08-26 鲁南制药集团股份有限公司 一种重组FGF21-Fc融合蛋白冻干粉制剂
EP3736574A1 (en) * 2019-05-07 2020-11-11 Atlas Antibodies AB A formulation comprising an isotope labeled fusion polypeptide
CN114853908B (zh) 2019-05-16 2024-06-07 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
CN112386575B (zh) * 2019-08-19 2023-03-21 鲁南制药集团股份有限公司 一种代谢调节融合蛋白的冻干制剂
AU2020345943A1 (en) 2019-09-10 2022-03-31 Obsidian Therapeutics, Inc. CA2-IL15 fusion proteins for tunable regulation
KR20220119424A (ko) 2019-12-20 2022-08-29 노파르티스 아게 인테그린 억제제를 사용한 간 질환의 조합 치료
JP6924291B2 (ja) 2020-01-21 2021-08-25 シャープ株式会社 端末装置、方法、および、集積回路
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
JP2023540663A (ja) * 2020-07-02 2023-09-26 サノフイ Ｇｌｐ－１ｒアゴニスト／ｆｇｆ２１融合タンパク質
WO2022101853A1 (en) 2020-11-16 2022-05-19 Novartis Ag Method of determining liver fibrosis
CN113265007B (zh) 2021-06-10 2022-02-15 江南大学 一种治疗代谢疾病的融合蛋白及其制备方法和应用
CN115286705B (zh) * 2021-12-30 2024-05-10 长江大学 一种黄鳝成纤维细胞因子21重组蛋白及其制备方法和应用
WO2023245543A1 (en) * 2022-06-23 2023-12-28 Ampsource Biopharma Shanghai Inc. Uses of fgf21 fusion proteins
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
WO2025108432A1 (en) * 2023-11-23 2025-05-30 Therorna Shanghai Co., Ltd. Circular rna encoding fgf21 and the use thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
EP0315456B1 (en) 1987-11-05 1994-06-01 Hybritech Incorporated Polysaccharide-modified immunoglobulins having reduced immunogenic potential or improved pharmacokinetics
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
AU1922101A (en) 1999-11-18 2001-05-30 Chiron Corporation Human fgf-21 gene and gene expression products
WO2001046261A1 (en) 1999-12-23 2001-06-28 Zymogenetics, Inc. Method for treating inflammation
WO2003011213A2 (en) 2001-07-30 2003-02-13 Eli Lilly And Company Method for treating diabetes and obesity
US7217798B2 (en) 2003-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of Fc-fusion protein serum half-lives by mutagenesis
BRPI0416683A (pt) * 2003-12-10 2007-01-30 Lilly Co Eli muteìna de fator de crescimento de fibroblasto de humano 21 (fgf-21), ou um seu peptìdeo biologicamente ativo, polinucleotìdeo, vetor de expressão, célula hospedeira, processo para produzir um polipeptìdeo, composição farmacêutica, método para tratar um paciente, e, uso da muteìna fgf-21
DE602005016917D1 (de) * 2004-05-13 2009-11-12 Lilly Co Eli Fgf-21-fusionsproteine
EA011390B1 (ru) * 2004-09-02 2009-02-27 Эли Лилли Энд Компани Мутантные белки (мутеины) фактора роста фибробластов 21
WO2006078463A2 (en) 2005-01-21 2006-07-27 Eli Lilly And Company Method for treating cardiovascular disease
JOP20190083A1 (ar) * 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
US8785151B2 (en) 2008-10-24 2014-07-22 Bernhard Geierstanger Biosynthetically generated pyrroline-carboxy-lysine and site specific protein modifications via chemical derivatization of pyrroline-carboxy-lysine and pyrrolysine residues
UY38740A (es) 2009-05-05 2020-12-31 Amgen Inc Mutantes de fgf21 y usos del mismo
JP2012525847A (ja) 2009-05-05 2012-10-25 アムジエン・インコーポレーテツド Ｆｇｆ２１変異体およびその使用
AU2010262927A1 (en) * 2009-06-17 2012-01-19 Amgen Inc. Chimeric FGF19 polypeptides and uses thereof
TW201130511A (en) 2009-12-22 2011-09-16 Novartis Ag Soluble proteins for use as therapeutics
DE102010038140B4 (de) * 2010-10-13 2020-06-18 Hettich-Heinze Gmbh & Co. Kg Beschlag für eine Schiebetür
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
TW201315742A (zh) 2011-09-26 2013-04-16 Novartis Ag 治療代謝病症之雙功能蛋白質
US9006400B2 (en) 2011-09-26 2015-04-14 Novartis Ag Fibroblast growth factor-21-Fc fusion proteins
JP6712230B2 (ja) 2014-03-11 2020-06-17 ノバルティス アーゲー リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020007314A (ja) * 2011-09-26 2020-01-16 ノバルティス アーゲー 代謝障害を処置するための融合タンパク質

Also Published As

Publication number Publication date
RS62341B1 (sr) 2021-10-29
EP3321276B1 (en) 2021-07-28
CN107266579A (zh) 2017-10-20
DK2760475T3 (en) 2018-10-15
CN107266579B (zh) 2022-07-12
GT201400055A (es) 2017-09-28
KR20140069250A (ko) 2014-06-09
AP2014007543A0 (en) 2014-03-31
CA2849464A1 (en) 2013-04-04
US20210386824A1 (en) 2021-12-16
SG11201400538QA (en) 2014-06-27
HRP20181558T1 (hr) 2018-11-30
US20150166622A1 (en) 2015-06-18
AR123908A2 (es) 2023-01-25
HK1251238A1 (en) 2019-01-25
CY1120928T1 (el) 2019-12-11
US11944664B2 (en) 2024-04-02
MX350273B (es) 2017-08-31
JP2014534172A (ja) 2014-12-18
PL2760475T3 (pl) 2018-11-30
AR088044A1 (es) 2014-05-07
HRP20211575T1 (hr) 2022-02-04
PE20181159A1 (es) 2018-07-19
HUE039857T2 (hu) 2019-02-28
PE20141551A1 (es) 2014-10-26
SI2760475T1 (sl) 2018-10-30
EP3321276A2 (en) 2018-05-16
ES2895080T3 (es) 2022-02-17
SMT202100595T1 (it) 2022-01-10
CU24314B1 (es) 2018-02-08
CU20150171A7 (es) 2016-07-29
CO6920257A2 (es) 2014-04-10
PL3321276T3 (pl) 2022-01-17
CU24206B1 (es) 2016-10-28
MX2014003677A (es) 2014-04-30
AU2012316052A1 (en) 2014-04-17
TWI593708B (zh) 2017-08-01
UY39119A (es) 2021-04-30
JP6567613B2 (ja) 2019-08-28
MA35437B1 (fr) 2014-09-01
US20240261372A1 (en) 2024-08-08
US20180369332A1 (en) 2018-12-27
IL231533B (en) 2018-06-28
TN2014000109A1 (en) 2015-07-01
ES2689762T3 (es) 2018-11-15
US20130079500A1 (en) 2013-03-28
ZA201401700B (en) 2015-01-28
JP2022058546A (ja) 2022-04-12
WO2013049247A1 (en) 2013-04-04
JP2018023370A (ja) 2018-02-15
KR102085605B1 (ko) 2020-03-06
BR112014007069A2 (pt) 2017-03-28
HUE055584T2 (hu) 2021-12-28
LT2760475T (lt) 2018-10-25
CN103945871A (zh) 2014-07-23
CL2016002215A1 (es) 2016-10-28
UY34346A (es) 2013-04-30
UA113856C2 (xx) 2017-03-27
CA2849464C (en) 2024-01-30
SI3321276T1 (sl) 2021-11-30
CU20140034A7 (es) 2014-08-28
IN2014DN02043A (cg-RX-API-DMAC7.html) 2015-05-15
CN103945871B (zh) 2017-04-26
TW201326213A (zh) 2013-07-01
CL2014000736A1 (es) 2014-10-03
EP3321276A3 (en) 2018-06-20
CR20140140A (es) 2014-07-15
NZ622998A (en) 2016-07-29
LT3321276T (lt) 2021-11-10
RS57868B1 (sr) 2018-12-31
US20160193297A1 (en) 2016-07-07
BR112014007069B1 (pt) 2020-12-15
CY1124697T1 (el) 2022-07-22
SG10201602339XA (en) 2016-05-30
JO3476B1 (ar) 2020-07-05
JP7339372B2 (ja) 2023-09-05
DK3321276T3 (da) 2021-10-25
US9266935B2 (en) 2016-02-23
US11129874B2 (en) 2021-09-28
EA039633B1 (ru) 2022-02-18
EP2760475A1 (en) 2014-08-06
JP2020007314A (ja) 2020-01-16
EA201490695A1 (ru) 2015-10-30
MY166059A (en) 2018-05-22
EP2760475B1 (en) 2018-07-04
PT2760475T (pt) 2018-10-25
US9006400B2 (en) 2015-04-14
US10076554B2 (en) 2018-09-18
IL231533A0 (en) 2014-04-30
PT3321276T (pt) 2021-10-27

Similar Documents

Publication Publication Date Title
JP7339372B2 (ja) 代謝障害を処置するための融合タンパク質
JP6110304B2 (ja) Ｆｇｆ２１関連障害を処置する方法
JP6152380B2 (ja) 代謝障害を処置するためのデュアル機能性タンパク質
AU2015202304C1 (en) Fusion proteins for treating metabolic disorders
HK1251238B (en) Fusion proteins for treating metabolic disorders
HK1196286A (en) Fusion proteins for treating metabolic disorders
HK1196286B (en) Fusion proteins for treating metabolic disorders

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160621

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170607

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170704

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170731

R150 Certificate of patent or registration of utility model

Ref document number: 6186361

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250